TearScience releases dynamic meibomian gland imager

TearScience introduced the LipiScan, which dynamically images the meibomian glands in high definition.

The LipiScan was designed to produce high-definition images of meibomian glands that can be reviewed during routine work-ups within the average practice setting, according to a company press release.

“Amid growing recognition of meibomian gland dysfunction (MGD) as a core root cause of fluctuating vision and discomfort, we saw the need for a technology to make assessment of meibomian glands routine,” Joseph Boorady, OD, president and CEO of TearScience, said in the release. “We are proud to transform care and lead innovation for MGD. “LipiScan allows eye care practitioners to evaluate meibomian gland structure in all patients. Because it is largely caused by modern lifestyles, many patients are at risk for MGD including surgical, contact lens and dry eye patients.”

TearScience stated in the release that the company adjusted the prices of its LipiView II and LipiFlow equipment and treatment activators (disposables) over the past year. The company anticipates that the LipiScan will allow eye care professionals an affordable addition to efficiently assess meibomian glands.

TearScience introduced the LipiScan, which dynamically images the meibomian glands in high definition.

The LipiScan was designed to produce high-definition images of meibomian glands that can be reviewed during routine work-ups within the average practice setting, according to a company press release.

“Amid growing recognition of meibomian gland dysfunction (MGD) as a core root cause of fluctuating vision and discomfort, we saw the need for a technology to make assessment of meibomian glands routine,” Joseph Boorady, OD, president and CEO of TearScience, said in the release. “We are proud to transform care and lead innovation for MGD. “LipiScan allows eye care practitioners to evaluate meibomian gland structure in all patients. Because it is largely caused by modern lifestyles, many patients are at risk for MGD including surgical, contact lens and dry eye patients.”

TearScience stated in the release that the company adjusted the prices of its LipiView II and LipiFlow equipment and treatment activators (disposables) over the past year. The company anticipates that the LipiScan will allow eye care professionals an affordable addition to efficiently assess meibomian glands.